The University of Southampton
University of Southampton Institutional Repository

Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland

Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland
Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland
We sought to determine the potential impact of seven-valent pneumococcal conjugate vaccine on the incidence of invasive pneumococcal disease (IPD) among children in Scotland. Invasive pneumococci from blood and cerebrospinal fluid, isolated between 2000 and 2004 from all children aged less than 5 years in Scotland, were characterized by serotyping. Using reported efficacy data of the seven-valent pneumococcal conjugate vaccine (PCV7) along with likely coverage rates, we made an estimation of the potential impact on the incidence of IPD among children in Scotland. A total of 217 pneumococci were characterized into 22 different serogroups/types, the most common, in rank order, being 14, 19F, 6B, 18C, 23F, 9V, 4, 1, 19A, and 6A. Estimated serotype coverage for PCV7 was 76.5% in those aged less than 5 years of age but increased to 88.9% for those aged 1 year. By using serotype coverage and estimates of vaccine efficacy and uptake, the potential impact of the vaccine for those greater than 2 months of age, but less than 5 years, was estimated as 67.3%, leading to an average of 29 preventable cases per year. The introduction of PCV7 into the childhood immunization schedule would reduce the burden of pneumococcal disease in children, and the incidence would be particularly reduced in those children aged 1 year. Additional benefits may be gained in adults through herd protection. Continued surveillance of IPD is required before, during, and after the introduction of PCV7.
0095-1137
1224-1228
Clarke, S.C.
f7d7f7a2-4b1f-4b36-883a-0f967e73fb17
Jefferies, J.M.C.
9468e292-0b41-412d-9470-944e257c7bcf
Smith, A.J.
ff8197a7-2583-4dae-a9d2-ad9d73a2f937
McMenimen, J.
6300da10-5804-4a98-a0d5-529a2e49cfdf
Mitchell, T.J.
927279e4-ea84-4ad0-aa32-314f0f3ae8e9
Edwards, G.F.S.
2e33709f-7a3b-40d4-8b7b-f1f40f012f57
Clarke, S.C.
f7d7f7a2-4b1f-4b36-883a-0f967e73fb17
Jefferies, J.M.C.
9468e292-0b41-412d-9470-944e257c7bcf
Smith, A.J.
ff8197a7-2583-4dae-a9d2-ad9d73a2f937
McMenimen, J.
6300da10-5804-4a98-a0d5-529a2e49cfdf
Mitchell, T.J.
927279e4-ea84-4ad0-aa32-314f0f3ae8e9
Edwards, G.F.S.
2e33709f-7a3b-40d4-8b7b-f1f40f012f57

Clarke, S.C., Jefferies, J.M.C., Smith, A.J., McMenimen, J., Mitchell, T.J. and Edwards, G.F.S. (2006) Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland. Journal of Clinical Microbiology, 44 (4), 1224-1228. (doi:10.1128/JCM.44.4.1224-1228.2006).

Record type: Article

Abstract

We sought to determine the potential impact of seven-valent pneumococcal conjugate vaccine on the incidence of invasive pneumococcal disease (IPD) among children in Scotland. Invasive pneumococci from blood and cerebrospinal fluid, isolated between 2000 and 2004 from all children aged less than 5 years in Scotland, were characterized by serotyping. Using reported efficacy data of the seven-valent pneumococcal conjugate vaccine (PCV7) along with likely coverage rates, we made an estimation of the potential impact on the incidence of IPD among children in Scotland. A total of 217 pneumococci were characterized into 22 different serogroups/types, the most common, in rank order, being 14, 19F, 6B, 18C, 23F, 9V, 4, 1, 19A, and 6A. Estimated serotype coverage for PCV7 was 76.5% in those aged less than 5 years of age but increased to 88.9% for those aged 1 year. By using serotype coverage and estimates of vaccine efficacy and uptake, the potential impact of the vaccine for those greater than 2 months of age, but less than 5 years, was estimated as 67.3%, leading to an average of 29 preventable cases per year. The introduction of PCV7 into the childhood immunization schedule would reduce the burden of pneumococcal disease in children, and the incidence would be particularly reduced in those children aged 1 year. Additional benefits may be gained in adults through herd protection. Continued surveillance of IPD is required before, during, and after the introduction of PCV7.

Other
1224 - Other
Download (3kB)

More information

Published date: April 2006

Identifiers

Local EPrints ID: 151855
URI: https://eprints.soton.ac.uk/id/eprint/151855
ISSN: 0095-1137
PURE UUID: 804119f5-16fc-4ebd-9307-c3a4807894dd
ORCID for S.C. Clarke: ORCID iD orcid.org/0000-0002-7009-1548

Catalogue record

Date deposited: 18 Jun 2010 15:33
Last modified: 06 Jun 2018 12:39

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×